The NCT02905188 and NCT03146234 studies (Table 3) reported that patients with advanced GPC3+ HCC (Child-Pugh A), receiving autologous CAR-GPC3 T-cell therapy following cyclophosphamide and fludarabine had a tolerable toxicity profile with no grade 3/4 neurotoxicity. Here, GPC3 is linked to hepatocellular carcinoma.